Studies in the 1950s and 1960s led to the formulation of the lipid hypothesis, which proposed that elevated low-density lipoprotein (LDL) cholesterol was causally related to coronary heart disease (CHD) and that reducing it would reduce the risk of myocardial infarction and other coronary events.
3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, the rate-limiting enzyme in the cholesterol biosynthetic pathway, was an attractive target in the search for drugs to reduce plasma cholesterol concentrations.
Compactin and lovastatin, natural products with a powerful inhibitory effect on HMG-CoA reductase, were discovered in the 1970s, and taken into clinical development as potential drugs for lowering LDL cholesterol.
However, in 1980, trials with compactin were suspended for undisclosed reasons (rumoured to be related to serious animal toxicity). Because of the close structural similarity between compactin and lovastatin, clinical studies with lovastatin were also suspended, and additional animal safety studies initiated.
In 1982 some small-scale clinical investigations of lovastatin in very high-risk patients were undertaken, in which dramatic reductions in LDL cholesterol were observed, with very few adverse effects. After the additional animal safety studies with lovastatin revealed no toxicity of the type thought to be associated with compactin, clinical studies resumed.
Large-scale trials confirmed the effectiveness of lovastatin. Observed tolerability continued to be excellent, and lovastatin was approved by the US FDA in 1987.
Lovastatin at its maximal recommended dose of 80 mg daily produced a mean reduction in LDL cholesterol of 40%, a far greater reduction than could be obtained with any of the treatments available at the time. Equally important, the drug produced very few adverse effects, was easy for patients to take, and so was rapidly accepted by prescribers and patients. The only important adverse effect is myopathy/rhabdomyolysis. This is rare and occurs with all HMG-CoA reductase inhibitors.
Several other HMG-CoA reductase inhibitors, now widely known as statins, subsequently became available for prescription: simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastatin and rosuvastatin.
The mechanism of the reduction in LDL cholesterol by statins is now known not to be simply reduction in cholesterol biosynthesis. Induction of the LDL receptor is crucial to their effectiveness.
Although the basic lipid hypothesis had been validated by the late 1980s, the movement towards treating hypercholesterolaemia was questioned because overviews of trials of treatments from the pre-statin era suggested that although CHD events might be reduced, survival was not improved.
However, large-scale, long-term trials published during the last decade, such as the Scandinavian Simvastatin Survival Study (4S, 1994), The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID, 1998) and the Heart Protection Study (HPS, 2002) with simvastatin, have now provided unequivocal evidence of a reduction in all-cause mortality.
In 2001, cerivastatin was withdrawn by its manufacturer due to an excessive risk of rhabdomyolysis.
In HPS the risk of serious cardiovascular events was reduced by simvastatin regardless of LDL-cholesterol level.
In the 1950s and 1960s, it became apparent that elevated concentrations of plasma cholesterol were a major risk factor for the development of coronary heart disease, which led to the search for drugs that could reduce plasma cholesterol. One possibility was to reduce cholesterol biosynthesis, and the rate-limiting enzyme in the cholesterol biosynthetic pathway, 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, was a natural target. Here, I describe the discovery and development of lovastatin — the first approved inhibitor of HMG-CoA reductase — and the clinical trials that have provided the evidence for the ability of drugs in this class to reduce the morbidity and mortality associated with cardiovascular disease.
Subscribe to Journal
Get full journal access for 1 year
only $21.58 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Steinberg, D. & Gotto, A. M. Jr. Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. JAMA 282, 2043–2050 (1999). An excellent concise historical overview.
Kannel, W. B. Clinical misconceptions dispelled by epidemiological research. Circulation 92, 3350–3360 (1995).
Keys, A. et al. The seven countries study: 2,289 deaths in 15 years. Prev. Med. 13, 141–154 (1984).
Peto, R., Yusuf, S. & Collins, R. Cholesterol-lowering trials in their epidemiological context. Circulation 72, 451 (1985).
NIH Consensus Development Conference. Lowering blood cholesterol to prevent heart disease. NIH Consensus Development Conference Statement. Nutr. Rev. 43, 283–291 (1985).
Kirby, T. J. Cataracts produced by triparanol. (MER-29). Trans. Am. Ophthalmol. Soc. 65, 494–543 (1967).
Endo, A., Kuroda, M. & Tsujita, Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium. J. Antibiot. (Tokyo) 29, 1346–1348 (1976).
Endo, A., Tsujita, Y., Kuroda, M. & Tanzawa, K. Inhibition of cholesterol synthesis in vitro and in vivo by ML-236A and ML-236B, competitive inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Eur. J. Biochem. 77, 31–36 (1977).
Watanabe, Y. et al. Hypolipidemic effects of CS-500 (ML-236B) in WHHL-rabbit, a heritable animal model for hyperlipidemia. Atherosclerosis 38, 27–31 (1981).
Kuroda, M., Tsujita, Y., Tanzawa, K. & Endo, A. Hypolipidemic effects in monkeys of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Lipids 14, 585–589 (1979).
Tsujita, Y., Kuroda, M., Tanzawa, K., Kitano, N. & Endo, A. Hypolipidemic effects in dogs of ML-236B, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Atherosclerosis 32, 307–313 (1979).
Fears, R., Richards, D. H. & Ferres, H. The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reductase activity, on cholesterogenesis and serum cholesterol levels in rats and chicks. Atherosclerosis 35, 439–449 (1980).
Singer, I. I., Scott, S., Kazazis, D. M. & Huff, J. W. Lovastatin, an inhibitor of cholesterol synthesis, induces hydroxymethylglutaryl-coenzyme A reductase directly on membranes of expanded smooth endoplasmic reticulum in rat hepatocytes. Proc. Natl Acad. Sci. 85, 5264–5268 (1988).
Bergstrom, J. D. et al. Hepatic responses to inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase: a comparison of atorvastatin and simvastatin. Biochim. Biophys. Acta 1389, 213–221 (1998).
Alberts, A. W. et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl Acad. Sci. 77, 3957–3961 (1980). Alfred Alberts and colleagues described the discovery and properties of lovastatin (originally named mevinolin), the first statin developed for clinical use.
Mabuchi, H. et al. Effect of an inhibitor of 3-hydroxy-3-methyglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10-levels in patients with familial hypercholesterolemia. N. Engl. J. Med. 305, 478–482 (1981).
Mabuchi, H. et al. Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine. N. Engl. J. Med. 308, 609–613 (1983).
Tobert, J. A., Hitzenberger, G., Kukovetz, W. R., Holmes, I. B. & Jones, K. H. Rapid and substantial lowering of human serum cholesterol by mevinolin (MK-803), an inhibitor of hydroxymethylglutaryl-coenzyme A reductase. Atherosclerosis 41, 61–65 (1982).
Tobert, J. A. et al. Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, in healthy volunteers. J. Clin. Invest. 69, 913–919 (1982).
Bilheimer, D. W., Grundy, S. M., Brown, M. S. & Goldstein, J. L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl Acad. Sci. 80, 4124–4128 (1983).
Illingworth, D. R. & Sexton, G. J. Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia. J. Clin. Invest. 74, 1972–1978 (1984).
Thompson, G. R., Ford, J., Jenkinson, M. & Trayner, I. Efficacy of mevinolin as adjuvant therapy for refractory familial hypercholesterolaemia. Q. J. Med. 60, 803–811 (1986).
Havel, R. J. et al. Lovastatin (mevinolin) in the treatment of heterozygous familial hypercholesterolemia. A multicenter study. Ann. Intern. Med. 107, 609–615 (1987).
Lovastatin Study Group II. Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. JAMA 256, 2829–2834 (1986). The first multicentre study with lovastatin in patients with hypercholesterolaemia. Using an unusual hybrid parallel/crossover trial design, this Phase IIb study in 100 patients obtained useful information about the dose–response relationship, time to maximal effect and the relative efficacy of once and twice daily dosing.
Lovastatin Study Group III. A multicenter comparison of lovastatin and cholestyramine therapy for severe primary hypercholesterolemia. JAMA 260, 359–366 (1988).
Lovastatin Study Group IV. A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. Am. J. Cardiol. 66, 22b–30b (1990).
Tang, J. L. et al. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 316, 1213–1220 (1998).
Bradford, R. H. et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch. Intern. Med. 151, 43–49 (1991).
Gerson, R. J. et al. Animal safety and toxicology of simvastatin and related hydroxy-methylglutaryl-coenzyme A reductase inhibitors. Am. J. Med. 87, 28s–38s (1989).
Smith, P. F. et al. HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies. J. Pharmacol. Exp. Ther. 257, 1225–1235 (1991).
Downs, J. R. et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279, 1615–1622 (1998).
Coronary Drug Project. Clofibrate and niacin in coronary heart disease. JAMA 231, 360–381 (1975).
Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 251, 351–364 (1984).
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383–1389 (1994). This landmark study provided unequivocal evidence that lowering cholesterol with a statin reduced all-cause mortality. It essentially ended the cholesterol controversy.
Pedersen, T. R. et al. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study. Arch. Intern. Med. 156, 2085–2092 (1996). This paper provides an exploration of the safety of simvastatin in 4S, in more detail than was possible in the original paper.
Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7–22 (2002). One of the largest long-term clinical trials ever done, the Heart Protection Study demonstrated the benefit and safety of simvastatin in a broad array of patient types with coronary heart disease (CHD) or those at high risk of CHD due to diabetes or non-coronary atherosclerotic vascular disease, including those with low-density lipoprotein cholesterol well below the United Kingdom population average.
Shepherd, J. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med. 333, 1301–1307 (1995).
Sacks, F. M. et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001–1009 (1996).
The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N. Engl. J. Med. 339, 1349–1357 (1998).
Serruys, P. W. J. C. et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA 287, 3215–3222 (2002).
Sever, P. S. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149–1158 (2003).
Chylack, L. T. Jr, Mantell, G., Wolfe, J. K., Friend, J. & Rosner, B. Lovastatin and the human lens; results of a two year study. The MSDRL Study Group. Optom. Vis. Sci. 70, 937–943 (1993).
Schmidt, J., Schmitt, C. & Hockwin, O. No lens changes caused by simvastatin results from a prospective drug safety study. Lens Eye Toxic. Res. 7, 643–650 (1990).
Harris, M. L. et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Br. J. Ophthalmol. 79, 996–1002 (1995).
Schmidt, J., Schmitt, C., Hockwin, O., Paulus, U. & von Bergmann, K. Ocular drug safety and HMG-CoA-reductase inhibitors. Ophthalmic Res. 26, 352–360 (1994).
Laties, A. M. et al. Expanded clinical evaluation of lovastatin (EXCEL) study results. II. Assessment of the human lens after 48 weeks of treatment with lovastatin. Am. J. Cardiol. 67, 447–453 (1991).
Tolman, K. The liver and lovastatin. Am. J. Cardiol. 89, 1374–1380 (2002).
LaRosa, J., He, J. & Vupputuri, S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 282, 2340–2346 (1999).
Pedersen, T. R. et al. Follow-up study of patients randomized in the Scandinavian simvastatin survival study (4S) of cholesterol lowering. Am. J. Cardiol. 86, 257–262 (2000).
Eckernas, S. A. et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br. J. Clin. Pharmacol. 35, 284–289 (1993).
Kostis, J. B., Rosen, R. C. & Wilson, A. C. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J. Clin. Pharmacol. 34, 989–996 (1994).
Partinen, M. et al. Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia. Am. J. Cardiol. 73, 876–880 (1994).
Harrison, R. W. & Ashton, C. H. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br. J Clin. Pharmacol. 37, 231–236 (1994).
Gengo, F. et al. Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin. Cardiol. 18, 209–214 (1995).
Wardle, J. et al. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group. BMJ 313, 75–78 (1996).
Norman, D. J., Illingworth, D. R., Munson, J. & Hosenpud, J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N. Engl. J. Med. 318, 46–47 (1988).
Pierce, L. R., Wysowski, D. K. & Gross, T. P. Myopathy and rhabdomyolysis associated with lovastatin–gemfibrozil combination therapy. JAMA 264, 71–75 (1990).
Gruer, P., Vega, J., Mercuri, M., Dobrinska, M. & Tobert, J. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am. J. Cardiol. 84, 811–815 (1999).
Ballantyne, C. M. et al. Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. 163, 553–564 (2003).
Brown, M. S. & Goldstein, J. L. A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34–47 (1986). A summary of the work that won the authors the Nobel Prize for Medicine or Physiology in 1985.
Pappu, A. S. & Illingworth, D. R. Contrasting effects of lovastatin and cholestyramine on low-density lipoprotein cholesterol and 24-hour urinary mevalonate excretion in patients with heterozygous familial hypercholesterolemia. J. Lab. Clin. Med. 114, 554–562 (1989).
Naoumova, R. P. et al. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis 119, 203–213 (1996).
Brown, M. S. & Goldstein, J. L. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J. Lipid Res. 21, 505–517 (1980).
Balasubramaniam, S., Goldstein, J. L. & Brown, M. S. Regulation of cholesterol synthesis in rat adrenal gland through coordinate control of 3-hydroxy-3-methylglutaryl coenzyme A synthase and reductase activities. Proc. Natl Acad. Sci. 74, 1421–1425 (1977).
Bergstrom, J. D., Wong, G. A., Edwards, P. A. & Edmond, J. The regulation of acetoacetyl-CoA synthetase activity by modulators of cholesterol synthesis in vivo and the utilization of acetoacetate for cholesterogenesis. J. Biol. Chem. 259, 14548–14553 (1984).
Kovanen, P. T., Bilheimer, D. W., Goldstein, J. L., Jaramillo, J. J. & Brown, M. S. Regulatory role for hepatic low density lipoprotein receptors in vivo in the dog. Proc. Natl Acad. Sci. 78, 1194–1198 (1981).
Ma, P. T. et al. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc. Natl Acad. Sci. 83, 8370–8374 (1986).
Reihnér, E. et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N. Engl. J. Med. 323, 224–228 (1990).
Arad, Y., Ramakrishnan, R. & Ginsberg, H. N. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism 41, 487–498 (1992).
Marais, A. D. et al. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J. Lipid Res. 38, 2071–2078 (1997).
Raal, F. J. et al. Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis 135, 249–256 (1997).
Steinberg, D. The cholesterol controversy is over. Why did it take so long? Circulation 80, 1070–1078 (1989).
Muldoon, M. F., Manuck, S. B. & Matthews, K. A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 301, 309–314 (1990).
Davey Smith, G. & Pekkanen, J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 304, 431–434 (1992).
Expert panel on detection evaluation and treatment of high blood cholesterol in adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA 269, 3015–3023 (1993).
Pyörälä, K. et al. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur. Heart J. 15, 1300–1331 (1994).
Blankenhorn, D. H. et al. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). The MARS Research Group. Ann. Intern. Med. 119, 969–976 (1993).
MAAS investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 344, 633–638 (1994).
Waters, D. et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89, 959–968 (1994).
Jukema, J. W. et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91, 2528–2540 (1995).
Pitt, B. et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J. Am. Coll. Cardiol. 26, 1133–1139 (1995).
Furberg, C. D. et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group Circulation 90, 1679–1687 (1994).
Salonen, R. et al. Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 92, 1758–1764 (1995).
Oliver, M. F. Serum cholesterol — the knave of hearts and the joker. Lancet 2, 1090–1095 (1981).
Oliver, M. F. Is cholesterol reduction always safe? Eur. J. Clin. Invest. 22, 441–442 (1992).
Oliver, M., Poole-Wilson, P., Shepherd, J. & Tikkanen, M. Lower patients' cholesterol now. BMJ 310, 1280–1281 (1995).
Collins, R. & MacMahon, S. Reliable assessment of the effects of treatment on mortality and major morbidity. I: clinical trials. Lancet 357, 373–380 (2001). An excellent guide to the concepts underlying the 'megatrial', such as the large long-term clinical trials that have been crucial to the success of the statins.
LaRosa, J. C. Pleiotropic effects of statins and their clinical significance. Am. J. Cardiol. 88, 291–293 (2001).
Vita, J. A. et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 102, 846–851 (2000).
Vollmer, T. et al. An open-label, single arm study of simvastatin as a therapy for multiple sclerosis (MS). 55th Annual Meeting of the American Association of Neurology Abstract S11. 004 (2003).
Raine, J. M. Withdrawal of cerivastatin (Libobay) by Bayer PLC. (Department of Health, Medicines Control Agency, London, 2001).
Editorial. How a statin might destroy a drug company. Lancet 361, 793 793 (2003).
Magarian, G. J., Lucas, L. M. & Colley, C. Gemfibrozil-induced myopathy. Arch. Intern. Med. 151, 1873–1874 (1991).
Backman, J., Kyrklund, C., Neuvonen, M. & Neuvonen, P. Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin. Pharmacol. Ther. 72, 685–691 (2002).
Stein, E. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety. Am. J. Cardiol. 82, 40j–46j (1998).
Yusuf, S. Two decades of progress in preventing vascular disease. Lancet 360, 2–3 (2002). An editorial on the Heart Protection Study that summarizes the advances made with statins and other drugs for preventing cardiovascular morbidity and mortality.
MacMahon, M. et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr. Metab. Cardiovasc. Dis. 10, 195–203 (2000).
Davidson, M. H. Statin trials in progress: unanswered questions. Curr. Atheroscler. Rep. 3, 9–13 (2001).
Bruckert, E. New lipid-modifying therapies. Expert Opin. Investig. Drugs 12, 325–335 (2003).
I am indebted to the following individuals for their careful review and helpful comments: D. Bilheimer, R. Collins, C. Newman, D. Steinberg, S.Wright and J. Vega.
Online Mendelian Inheritance in Man
Encyclopedia of Life Sciences
- MYOCARDIAL INFARCTION
Popularly known as a heart attack, this is the death of part of the heart muscle due to sudden loss of blood supply. Typically, the loss of this supply is caused by a complete blockage of a coronary artery containing athersclerotic plaque by a blood clot.
- CORONARY HEART DISEASE
(CHD). A condition in which the main arteries supplying the heart contain atherosclerotic plaque, which can cause myocardial infarction (see above) or angina pectoris, in which cardiac blood flow is reduced, leading to heart pain on exercise. Atherosclerotic plaque contains macrophages and cholesterol.
Framingham is a Massachusetts town considered representative of the United States population, and the epidemiology of cardiovascular disease still continues to be studied there after more than half a century.
- FAMILIAL HYPERCHOLESTEROLAEMIA
(FH). This is an autosomal dominant condition characterized by a defective allele coding for the low-density lipoprotein (LDL) receptor, which causes gross elevations of plasma LDL cholesterol.
- ORPHAN DRUG
An agent that is useful for diseases too rare to provide more than minimal commercial potential is known as an orphan drug.
About this article
Cite this article
Tobert, J. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2, 517–526 (2003). https://doi.org/10.1038/nrd1112
A novel strategy: A consecutive reaction was used to distinguish in the presence of statins between normal cells and cancer cells
Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy (2020)
Dietary Cholesterol Exacerbates Statin-Induced Hepatic Toxicity in Syrian Golden Hamsters and in Patients in an Observational Cohort Study
Cardiovascular Drugs and Therapy (2020)
Monitoring of Aspergillus terreus morphology for the lovastatin production in submerge culture by impedimetry
Biochemical Engineering Journal (2020)
Current Pharmaceutical Design (2020)
Metal‐Free Aerobic Sulfenyllactonization of Unsaturated Carboxylic Acids with Thiols Using Air as Sole Oxidant